ASMB Assembly Biosciences Inc.

15.7
-0.87  -5%
Previous Close 16.57
Open 16.3
Price To Book 1.9
Market Cap 401131185
Shares 25,549,757
Volume 145,344
Short Ratio
Av. Daily Volume 351,657

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data from second trial did not meet primary endpoint - Feb 2014. Will not pursue future development
VEN 307 (diltiazem cream)
Anal fissures
Phase 2a final data due later in 2019.
ABI-H0731
Hepatitis B virus (HBV)
Phase 1a poster presented at EASL April 11, 2019.
ABI-H2158
Hepatitis B virus (HBV)

Latest News

  1. Here's Why Assembly Biosciences Is Slipping Today
  2. Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019
  3. Assembly Biosciences Presents Data Highlighting Next-Generation HBV Core Protein Inhibitors at EASL 2019
  4. 4 Biotech Stocks With Major Catalysts in April
  5. Assembly Biosciences Announces Multiple Abstracts Highlighting HBV Core Inhibitor Portfolio Accepted for Oral and Poster Presentations at EASL 2019
  6. Assembly Biosciences to Participate in the Jefferies 2019 HBV Summit
  7. If You Had Bought Assembly Biosciences Stock Three Years Ago, You Could Pocket A 261% Gain Today
  8. Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results
  9. Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects
  10. Market Trends Toward New Normal in Brighthouse Financial, BioMarin Pharmaceutical, EZCORP, Assembly Biosciences, A-Mark Precious Metals, and American Public Education — Emerging Consolidated Expectations, Analyst Ratings
  11. Mylan (MYL) Jumps: Stock Rises 7.1%
  12. Assembly Biosciences, Inc. (NASDAQ:ASMB) Insiders Increased Their Holdings
  13. Assembly Biosciences Announces Completion of Enrollment in Two Phase 2a Studies with ABI-H0731 for Chronic Hepatitis B Virus
  14. Here is What Hedge Funds Think About Assembly Biosciences Inc (ASMB)
  15. Amphastar Pharmaceuticals (AMPH) Catches Eye: Stock Jumps 6.7%
  16. Should You Worry About Assembly Biosciences Inc’s (NASDAQ:ASMB) CEO Pay?
  17. Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD
  18. Assembly Biosciences (ASMB) Reports Q3 Loss, Tops Revenue Estimates
  19. Assembly Biosciences: 3Q Earnings Snapshot
  20. Assembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update